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Abstract
Polyamidoamine (PAMAM)-entrapped Au nanoparticles were synthesized with distinct sizes to figure out the
size effect of Au-based contrast agent on CT imaging of passively targeted tissues. Au/PAMAM nanoparticles
were first synthesized with narrow distribution of particles size of 22.2 ± 3.1, 54.2 ± 3.7, and 104.9 ± 4.7 nm in
diameters. Size effect leads no significant difference on X-ray attenuation when Au/PAMAM was ≤0.05 mol/L.
For CT imaging of a tumor model, small Au/PAMAM were more easily internalized via endocytosis in the
liver, leading to more obviously enhanced contrast. Similarly, contrast agents with small sizes were more
effective in tumor imaging because of the enhanced permeability and retention effect. Overall, the particle
size of Au/PAMAM heavily affected the efficiency of CT enhancement in imaging RES and tumors.
Keywords: Size effect, Computed tomography, Au nanoparticles, Reticuloendothelial system, Tumor tissue,
Passive targeting
Background
Being different with classical diagnostic imaging, molecular
imaging sets forth to probe the molecular abnormalities
that are the basis of disease rather than to image the end
effects of these molecular alterations [1, 2]. The physico-
chemical features of the imaging agent, such as morphology
and particle size, play an important role in image quality.
Although CT imaging is not commonly used as a
molecular imaging tool in clinical practice because of the
fine performance in high spatial resolution and short acqui-
sition time, CT-relevant targeted and specific contrast
agents were also rapidly developed recently, aiming to a
strongly selective X-ray attenuation and corresponding
enhanced contrast. The specifically physical features of light
scattering and surface plasmonic properties made Au nano-
particles (AuNPs) promising materials as CT contrast
agents for molecular imaging. Up to date, iodine with high
X-ray attenuation efficiency is still the most common CT
contrast agent. Comparing with iodine, Au has a larger
atomic number (79) and electric density (19.32 G/cm3),
leading to greater coefficient of X-ray attenuation [3, 4].
Previous reports stated that AuNPs serves as the non-
cytotoxicity agents, and does not involve in biological
process, where no biological toxicity risk such as renal
toxicity and vascular permeation will be introduced [5].
As CT contrast agents, dendrimers-entrapped AuNPs
were extensively studied, and the previous studies mainly
focused on the in vitro efficiency of X-ray attenuation [6, 7]
and targeting delivery [8]; however, the size effect on bioap-
plications were still not totally understood. After being
coated with polyethylene glycol (PEG) or dendrimers, blood
circulation time was markedly prolonged, and improved
biocompatibility was achieved [9–11]. Thus, PEG-coated
AuNPs and dendrimers-coated AuNPs were normally
regarded as contrast agent of blood pool and lymph node,
further applied in tumor-related diagnosis [12, 13]. The
flexibility of surface modification made multimodal
imaging, such as CT/MR and CT/optical dual modal
imaging, achievable according to the conjugation of other
imaging tracers [14–16].
Introduction of targeting molecules such as specific
protein, biomarkers and aptamer, make the contrast
agents actively targeting specific molecules. Although
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active targeting is the common mechanism of contrast
enhancement, the passive targeting is rightfully inevit-
able, and dominates the distribution of Au/polyami-
doamine (PAMAM). Actually, targeting efficiency is
partially determined by the morphology and size, so
the associated effect is not negligible. Previous studies
have shown that morphology may cause significant
differences on the biodistribution and have an obvious
effect on blood circulation [17, 18]. Correspondingly,
distinct size may also bring factual effect both in vitro
and in vivo. As nanoscale particles, because of the
passively targeting for the reticuloendothelial cells and
the enhanced permeability and retention (EPR) effect
in the blood vessels of tumor tissue, the accumulation
of Au/PAMAM in reticuloendothelial system (RES)
macrophages and tumor tissues closely depends on
the particle size. Therefore, it is necessary to investi-
gate the size effect on CT imaging of the passively
targeted organs and tissues.
So far, Au nanoparticles with uniform size between 5
and 200 nm were widely applied in the field of not only
CT imaging but also the drug delivery [19, 20] and
radiosensitizer [21]. The aim of this study is to
synthesize Au/PAMAM nanoparticles with distinct
diameters and explore the influence of diameter on X-
ray attenuation in vitro and CT imaging in vivo, particu-
larly on RES uptake and EPR effect, so as to determine
the optimal size of Au/PAMAM as contrast agents.
Methods
Synthesis of Au/PAMAM
The schematic procedure of Au/PAMAM contrast agents
is shown in Fig. 1a. HAuCl4 was dissolved in 100 mL
distilled water at 0.1 mg/mL and then heated to 100 °C in
nitrogen atmosphere. A suitable amount of sodium citrate
solution at 10 mg/mL was added as a reducing agent, and
reaction system was refluxed for another 10 min. After
naturally cooling down, Au nanoparticles were collected
and purified via centrifuging at 12,000 rpm for 1 min.
Surface coating was performed following an established
method [22, 23]. The fifth generation (G5.0) PAMAM
dendrimers in methanol were mixed with N-hydroxysucci-
nimidyl 3-mercaptopropanoate in 1:1 mixed solution of
tetrahydrofuran and methanol and vortexed for 1 h at room
temperature. The PAMAM-SH and AuNPs reacted over-
night utilizing the strong affinity between thiol groups and
AuNPs and product was collected via centrifuging as well.
Characterization of particle size and X-ray attenuation
Morphology of Au nanoparticles was observed by trans-
mission electron microscopy (TEM) (H-800; Hitachi,
Chiyoda, Tokyo, Japan) operating at 200 kV. A region of
interest (ROI) with more than 100 particles was outlined
in the TEM images, and particle distribution was
analyzed using ImageJ. Au/PAMAM solution was
concentrated and quantified with inductively coupled
plasma-atomic emission spectrometry (ICP-AES). X-ray
attenuations of diluted Au/PAMAM solution were
measured at concentration ranging from 0.002 to
0.1 mol/L (0.002, 0.005, 0.01, 0.02, 0.05, 0.1 mol/L) by a
CT scanner (Somatom Sensation 16; Siemens Health-
care, Forchheim, Germany) with tube voltage 120 kV,
tube current 50 mA, field of view (FOV) 25 cm, matrix
512 × 512, slice thickness 1 mm, and gap 0 mm.
Contrast agents with distinct sizes were measured in the
same condition and with three replications.
CT scanning
Nine A549 tumor-bearing BALB/c nude mice (weight 20–
25 g, female) were recruited in this research. Animal care
and all experimental procedures were approved by and
followed the guidance of the Animal Care Committee of
Tianjin Medical University Cancer Institute and Hospital.
Tumors were located in the right posterior limb, and mice
were raised in a SPF-class environments. Au/PAMAM
contrast agent was injected intravenously at a dosage of
100 μL (0.1 mol/L, in 0.9 % sodium chloride injection) per
20 g body weight. Mice were scanned with a micro-CT
scanner (VECTor+/CT; Milabs B.V., Netherlands) at 1 and
4 h post injection under anesthesia with the following
parameters: tube voltage 55 kV, tube current 615 μA, FOV
45 mm, slice thickness 10 μm, and gap 0 mm. Quantitative
analysis of CT values of ROIs at corresponding time points
were performed. Attentions were focused on the size
effect of Au/PAMAM on enhancements of image
contrast on RES, particularly on the liver, and the size
effect of Au/PAMAM on enhancements of image
contrast on xenograft tumor.
In vitro and ex vivo verifications
For Au/PAMAM CT imaging of tumor, contrast agent
extravasates through the enlarged endothelial gaps and
deposits in the loose connective tissue space. The whole
procedure heavily depends on the particle size. Due to
low concentration of gold in vivo, after the CT scanning,
mice were sacrificed for quantitative analysis of Au
element, which was conducted by ICP-AES. The same
measurements were performed for the quantitative
analysis of Au element in the liver as well. In order to
testify the biosafety in acute period, tumorous tissues
was stained via HE staining to observe the Au/PAMAM
induced changes of cell morphology.
In order to verify the observations on CT imaging of
RES-related organs, the size effect on in vitro endocytosis
was evaluated on murine macrophage-like RAW264.7 cells;
106 macrophages were incubated with 0.1 μg Au/PAMAM
in 0.5 mL DMEM for 1 and 4 h, and cellular uptake
efficiencies were quantified by a UV-Vis spectrophotometer
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Fig. 1 Synthetic scheme and characteristics of Au-based CT contrast agents with gradient sizes. a Synthesis of PAMAM-entrapped Au. b–d TEM
of Au nanoparticles in 22.2 ± 3.1, 54.2 ± 3.7, and 104.9 ± 4.7 nm. e Typical example of PAMAM-entrapped Au. f Size distributions of Au with three
distinct sizes
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(Alpha 1506; LASPEC, Shanghai, China) via the measure-
ments of absorbance of Au/PAMAM at 537 nm before and
after the incubation.
Results
As shown in Fig. 1b–d, f, sizes of Au nanoparticles were
restricted as 22.2 ± 3.1, 54.2 ± 3.7, and 104.9 ± 4.7 nm in
diameters with narrow and symmetric distributions.
Particle sizes were controlled by the amount of reducing
agent. During the synthetic procedures, 1.5, 1, and 0.4 mL
sodium citrate solution (10 mg/mL) corresponded to
AuNPs of 22.2, 54.2, and 104.9 nm, respectively. The less
reducing agent produced less crystal nucleus during the
early period of synthesis and determined the size of final
product. The size of crystal nucleus grown slowly in this
gentle reaction condition leading to the narrow distribution
of particle sizes. As shown in Fig. 1e, the PAMAM coating
covered AuNPs with a single layer of ca. 5 nm. The surface
coating utilizes the strong affinity between AuNPs and thiol
groups, so the existing PAMAM cover prevented the
further coating of PAMAM on the surface, leading to the
single layer of surface coating and functionalizing the
particle surface with abundant amino groups.
As depicted in Fig. 2, Au/PAMAM had a linearly
increased enhancing effect on X-ray attenuation relied
on the concentration of contrast agents. As shown in
the amplified graph, size did not lead to a significant
difference on X-ray attenuation for contrast agents with
concentration ≤0.05 mol/L.
The mean CT values of soft tissues were 33.6 Hounsfield
unit (HU) (before injection), 36.9 HU (for 22.2 nm),
36.2 HU (for 54.2 nm), and 35.9 HU (for 104.9 nm) at 4 h
post injection, and no significant difference was detected.
For the enhanced CT imaging of the liver (Fig. 3a), CT
values increased along with the accumulation of Au/
PAMAM, meanwhile, the increase depended on the
particle size (Fig. 3b), where the relatively small Au/
PAMAM accumulated in the liver more than the bigger
ones significantly (Fig. 3c). Size effect on enhancement of
liver imaging was observed that ΔHU= 48.0 for 22.2 nm,
ΔHU= 41.6 for 54.2 nm, and ΔHU= 37.3 for 104.9 nm
were detected at 4 h post injection. For the in vitro verifi-
cation of the size effect on endocytosis tested after 1 or
4 h co-incubation, a more obvious size effect-induced
difference on cellular uptake was detected that Au/
PAMAM with small sizes tended to uptake more than
others (Fig. 3d).
For the enhanced CT imaging of tumors (Fig. 4a–c),
tumorous tissues were more clearly outlined. In the
quantitative analysis (Fig. 4d), CT values increased along
with the accumulation of contrast agents, and size
effect-induced differences on ΔHU were amplified due
to the lasting accumulation of Au/PAMAM. No Au/
PAMAM-induced changes of cell morphology was
observed on HE staining (Fig. 4e), proving the biosafety
in acute period after injection. As the fundamental
reason of difference on CT enhancements, Au content
in tumor tissues heavily relied on the particle size
(Fig. 4f ), but an obviously lower level of Au accumula-
tion in the tumor was observed when compared with Au
content in the liver, this is why the ΔHU for tumor
imaging was smaller than the ΔHU in liver imaging.
Discussion
Two methods were commonly used in synthesis of Au/
PAMAM. For the Au/PAMAM with relatively small size,
Fig. 2 Au/PAMAM lead X-ray attenuation depending on concentration and particle size. The curve of HU values without significant difference
were circled in the orange box and amplified in the upper left corner
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PAMAM was utilized as the core, and Au element was
filled in the cage of PAMAM or attached to the surface of
PAMAM [9, 10]. Due to the limitation of PAMAM
generation, the size of this kind of Au/PAMAM was
restricted to less than 15 nm. For Au/PAMAM with bigger
size, AuNPs were used as the core, and thiolated PAMAM
was covered to the surface just like the method used in this
research. PAMAM with G4.0 and G5.0 was easily being
attached to the surface to form the stable complexes, but
the coating of PAMAM with lower generation was less
stable because of the easy aggregation resulted from the
low degree of grafting and related flexibility. In the design
of Au-based contrast agents, PAMAM stabilized the nano-
particles, improved the solubility and biocompatibility, and
further functionalized the AuNPs with more potentials,
such as active targeting and multimodal imaging modalities.
The targeting delivery to specific target or controlled
release in targeted tissues can be realized through
surface functionalization with targeting molecule. For
example, the dual-targeting for prostatic cancer was
realized via the conjugation of two targeting molecules
on PAMAM [24]. Other imaging tracers can be
labeled to Au/PAMAM via chemical reaction with
amino groups or via chemisorption. The labeling of
another imaging tracers, such as fluorescent dyes and
radionuclide, can realize the dual modal imaging with
enhanced CT [15, 16]. Furthermore, diagnosis and
therapy can be combined in one agent, and imaging
with more than two modalities can be achieved based
on the functionalization of Au/PAMAM as well.
Size heavily influenced on the in vivo endocytosis,
which is dominated by macrophages, but endocytosis
will also be affected by the intensity of blood flow and
elimination rate. As shown in the in vitro test, and
proved in previous research, the rate of particle uptake
depends strongly on the NP size, with the smaller sizes
internalized much more quickly than the larger ones
[25]. Relatively small particle size corresponds to heavy
endocytosis, forming the main reason of high uptake in
the liver, which contained abundant macrophages.
Hence, the primary cause leading to the difference on
CT imaging of RES is not the size effect on X-ray
attenuation, which is proved not obvious when concen-
tration was ≤0.05 mol/L, but the size effect-induced
difference on endocytosis efficiency of macrophages.
However, due to the confounding factors, such as blood
and vessels penalty, the size effect-induced in vivo
difference on CT values was not as obvious as the size
effect observed on endocytosis in vitro. During the early
period (1 h post injection), CT contrast was already
Fig. 3 Size effect of Au/PAMAM contrast agent on CT imaging of reticuloendothelial system. a Size effect on liver imaging, the typical images of
transverse slices of the top of liver were given. b Detailed CT values of liver imaging. c Au content in corresponding livers detected via ICP-AES at
4 h post injection. d In vitro verification of size effect on endocytosis tested after 1 h co-incubation (blank columns) and after 4 h co-incubation
(grey columns) with Au/PAMAM concentration at 10−7 μg/cell
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enhanced, but the size effect-induced difference on CT
imaging of the liver was not totally exhibited. The
enhancements on CT contrast were gradually strengthened
along with the increase of particle deposition. Meanwhile,
the difference among the three kinds of Au/PAMAM on
CT contrast also increased along with the gradual increase
of particle deposition. For most contrast agents, imaging
was performed soon after the injection. The longer time
means more confounding factors for the imaging results,
such as the individual difference. Secondly, based on
another research in our lab [21], most AuNPs will be
expelled at 6 h post injection or more. So, as a potential
preclinical research, imaging research focus on the 1 and
4 h post injection, and the difference resulted from longer
time was not explored.
For the EPR effect involved in tumor imaging,
although nearly all the particles with size less than
700 nm can passively target tumor, it is obvious that the
size effect exists for the penetration through new vessels
[26]. The smaller size facilitated the Au/PAMAM in
extravasating through the enlarged endothelial gaps in
tumors, leading to a more obviously enhanced CT
contrast. Utilizing this phenomenon, the drug carrier in
smaller size is normally with an increased delivering
efficiency [18].
This research was referable to passive targeting of other
nanoparticles. The size effect of Au/PAMAM on passive
targeting helped to figure out the in vivo mechanism of
AuNPs and similar nanoparticle-based agents. Both
optimizing the imaging of passively targeted organs and
providing reference for the design of actively targeting
imaging agents were achieved. Based on the observation on
Au/PAMAM-based CT imaging of the liver and tumor,
among the tested size range, 22.2 nm was the best choice
in drug designation. The superiority of enhanced passive
targeting resulted from small size, plus the active targeting
ability of targeting molecules, will doubly promote the
tumor-targeted imaging. However, the passive targeting for
RES-related organs will be strengthened at the same time.
In active targeting delivery which aims to avoid RES uptake,
the slight increase of the particle size will decrease the
passive target to RES effectively, but will not heavily
influence on the extravasating through the enlarged
endothelial gaps in tumors. Additionally, the potential
defect of longtime retention in macrophages that
resulted from small size should be paid more attention
Fig. 4 Size effect of Au-based contrast agent on CT imaging of subcutaneous A549 tumor. a–c CT imaging of tumor with 22.2, 54.2,
and 104.9 nm Au/PAMAM injected. d Detailed CT values of tumor imaging. e HE staining of tumor tissues where no changes of cell
morphology were observed. f Au content in corresponding tumors detected via ICP-AES at 4 h post injection
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when applied in vivo. Actually, 100–200 nm in
diameter is the usual size for the nanoparticle-based
drugs approved by FDA because of the relatively low
RES-related uptake and low cytotoxicity [27]. Hence, a
comprehensive consideration on the particle size was
need when designing a nanoparticle-based drug.
Due to the low resolution of micro-CT, the contrast
resulted from the introduction of imaging agents was
not totally exhibited, but proved by the quantitative
analysis of CT values. The size effect of contrast agents
could be more clearly exhibited in the bigger animal
models and with improved scanning techniques.
Conclusions
The size effect of Au/PAMAM has no obvious
influence on X-ray attenuation when Au/PAMAM was
≤0.05 mol/L but does have influence on the CT
imaging of living body. The size effect of Au/PAMAM
on endocytosis and EPR effect should be paid atten-
tion when applied in vivo, where nanoparticles with
relatively small size was more efficient in passive
targeting and enhancing image contrast.
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